New Survey Reveals Increasing Barriers for Women Seeking Birth Control and Disproportionate Impact on Women of Color
Faced with job losses and disruption from the pandemic, women find it more challenging in 2020 to access birth control, a critical aspect of women’s health San Francisco – November 18, 2020 – Medicines360, a global nonprofit women’s health pharmaceutical organization fighting to make access to medicines for all women a reality, today released the […]
Medicines360 Appoints Rolf Jansen as Vice President of Drug Development and Manufacturing
Jansen to Lead Product Expansion Focused on Essential Medicines Facing Access Challenges SAN FRANCISCO – July 17, 2020 – Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Rolf Jansen as the Vice President of Drug Development and Manufacturing. Mr. Jansen is a chemical engineer with more than thirty years of pharmaceutical experience developing […]
Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Reinforces Efficacy for Longest-Approved Duration of Use for a Hormonal IUS
SAN FRANCISCO – December 17, 2019 – Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg is highly efficacious in preventing pregnancy for up to six years of use. The publication also reports data related to the bleeding profile over the same period of […]
FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs
SAN FRANCISCO and DUBLIN – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing […]
Medicines360 Launches #NotAwkward Campaign to Encourage Positive Conversations about Birth Control and Reproductive Health
New survey finds the top access challenge cited by women is feeling uncomfortable discussing sex or birth control SAN FRANCISCO (September 16, 2019) – Medicines360, a nonprofit women’s health organization tackling the most pressing needs in women’s health, today announced the launch of #NotAwkward, a campaign to encourage positive conversations about birth control and reproductive […]
Medicines360 Awarded “Clinical Trial Result of the Year” at 2019 CARE Awards
SAN FRANCISCO – Medicines360, a nonprofit, global women’s health pharmaceutical company with a mission of expanding access to quality medicines, was awarded the Clinical Trial Result of the Year at the 2019 Clinical and Research Excellence (CARE) Awards. The CARE Awards celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing […]
Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.
Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting SAN FRANCISCO and DUBLIN – Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, presented new six-year data from Medicines360’s ongoing […]
Power to Decide and Medicines360 Announce Partnership to Expand Access to Contraception
WASHINGTON, D.C. – Today, millions of women in need of contraception struggle with access to this basic part of women’s health care. To help women access this needed service, Power to Decide and Medicines360, a mission-driven nonprofit women’s health pharmaceutical, will partner to help expand access to contraception for all women. This partnership aims especially to help […]
Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years
Data from ACCESS IUS, the largest ongoing Phase 3 clinical trial in the U.S. of an intrauterine system evaluating pregnancy prevention, also reports bleeding profile over five years in diverse women SAN FRANCISCO – Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA is highly efficacious in preventing pregnancy over five […]
FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
DUBLIN and SAN FRANCISCO – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for […]
